血清化物和结合循环和 thiazide 利尿剂对急性心力衰竭的反应:ALCALOTIC 研究
Julio Núñez1, Gema Miñana1, Maria Villalonga2
1Cardiology Department, Hospital Clínico de Valencia, INCLIVA, Valencia, Spain.
Internal and emergency medicine
|May 16, 2025
概括
急性心力衰竭患者的血清化物水平较低与尿液反应较差有关. 化物利尿剂可以改善体重减轻,但仅在没有低血症的患者中,这表明化物水平会影响治疗的有效性.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内部医学 内部医学
背景情况:
- 在心力衰竭 (HF) 病理生理学中的作用越来越被认可,特别是它与预后和利尿剂耐药性的关联.
- 了解血清化物水平对利尿剂有效性的影响,对于优化急性心力衰竭 (AHF) 管理至关重要.
研究的目的:
- 评估急性心力衰竭 (AHF) 患者在血清化物水平的范围内的利尿反应.
- 评估循环和 thiazide 利尿剂与基线血清化物度相关的有效性.
主要方法:
- 对前性多中心ALCALOTIC研究的一项子分析,该研究涉及386名因AHF入院的患者.
- 分析了作为主要终点的住院体重减轻,根据基线血清化物水平分层 (低血症,正常血症,高血症).
- 评估尿液治疗 (循环和 thiazide) 与减肥之间的关联,考虑到血清化物水平和相互作用效应.
主要成果:
- 低血症 (<96 mmol/L) 与正常血症 (≥96 mmol/L) 相比,独立地与出院时显著较小的体重减轻有关.
- 将 thiazide 利尿剂添加到循环利尿剂中,在总人口中增加了体重减轻.
- 观察到一种显著的相互作用: thiazides 改善了normochloraemic 和 hyperchloraemic 患者的体重减轻,但在那些患有低血的人中没有.
结论:
- 低血症与急性心力衰竭住院患者的尿液反应恶化有关.
- 酸性利尿剂增强了利尿反应,但这种益处仅限于血清化物水平正常或高的患者,而不是低血症患者.
- 在治疗急性心力衰竭时,应考虑血清化物水平,以优化治疗结果.
相关概念视频
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:29Roles of Electrolytes: Chloride and Bicarbonate
Chloride ions contribute to the osmotic pressure gradient distinguishing the intracellular fluid (ICF) from the extracellular fluid (ECF). They counterbalance positively charged ions in the ECF and ensure its electrochemical stability. The renal system's process of chloride absorption and release generally mirrors that of sodium ions.
Conditions such as hypochloremia can arise from insufficient chloride reabsorption by the kidneys, often compounded by extended bouts of diarrhea, vomiting, or...
Conditions such as hypochloremia can arise from insufficient chloride reabsorption by the kidneys, often compounded by extended bouts of diarrhea, vomiting, or...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.